Mandate

Vinge advises Hansa Biopharma in connection with a directed share issue

July 13, 2020

The board of directors of Hansa Biopharma has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby Hansa Biopharma will raise proceeds of SEK 1.1 billion, before issue costs.

The share issue was made on the basis of an accelerated bookbuilding process carried out by Morgan Stanley, Kempen & Co and Zonda Partners, and was multiple times oversubscribed due to high demand from US, European and Swedish institutional investors.

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)- mediated autoimmune conditions, transplant rejection and cancer.

Vinge’s team consisted of Dain Hård Nevonen, Malte St Cyr Ohm, Stephanie Stiernstedt and Hampus Olsson.

 

Guidance judgment on the criminal liability for ordering a cabotage transport

The ordering of a road transport made by one of the largest freight forwarders in Sweden has been considered in accordance with the conditions for legal cabotage transports through a decision from the Court of Appeal over Skåne and Blekinge. The Court of Appeal, thus, changes the District Court’s judgment and acquits the freight forwarder. The central issue in the case was how the number of cabotage transports should be calculated.
May 07, 2021

The Scope of Work According to AB 04

One of the most important parts of a construction agreement is the part where the scope of work is defined. There is a major difference between finding scope of work issues early in a construction project, instead of later during the execution phase.
May 04, 2021

A shift in EU merger control policy and practice could affect deal certainty and create opportunities for complainants

The European Commission is expanding its control of mergers and acquisitions within the existing legal framework, allowing national authorities to refer a transaction they do not have jurisdiction over for review in Brussels.
April 26, 2021